Akebia Therapeutics' stock is down 28% after a proposed stock offering, with declining Auryxia revenues and significant financial challenges. Vafseo's market launch shows some promise, but it's a ...

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted ...

Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. As the U.S. market experiences heightened volatility ...

In the past 30 days, 2024 loss estimates for Akebia have improved from 28 cents per share to 19 cents per share. For 2025, loss estimates have improved from 23 cents to 17 cents per share in the ...

CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended ...

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...

The latest price target for Akebia Therapeutics (NASDAQ:AKBA) was reported by HC Wainwright & Co. on April 4, 2025. The analyst firm set a price target for $7.50 expecting AKBA to rise to within ...

Akebia Therapeutics shares were down 20% to $2.27 after the company priced its underwritten public offering of 25 million shares at $2 a share. All shares are being offered by Akebia. The proceeds ...

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics (AKBA) ®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the ...